Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells
Tanja Waldmann1, Eugen Rempel, Nina V Balmer
1Doerenkamp-Zbinden Chair for in Vitro Toxicology and Biomedicine, University of Konstanz , 78457 Konstanz, Germany.
Abstract:
Information on design principles governing transcriptome changes upon transition from safe to hazardous drug concentrations or from tolerated to cytotoxic drug levels are important for the application of toxicogenomics data in developmental toxicology. Here, we tested the effect of eight concentrations of valproic acid (VPA; 25-1000 μM) in an assay that recapitulates the development of human embryonic stem cells to neuroectoderm. Cells were exposed to the drug during the entire differentiation process, and the number of differentially regulated genes increased continuously over the concentration range from zero to about 3000. We identified overrepresented transcription factor binding sites (TFBS) as well as superordinate cell biological processes, and we developed a gene ontology (GO) activation profiler, as well as a two-dimensional teratogenicity index. Analysis of the transcriptome data set by the above biostatistical and systems biology approaches yielded the following insights: (i) tolerated (≤25 μM), deregulated/teratogenic (150-550 μM), and cytotoxic (≥800 μM) concentrations could be differentiated. (ii) Biological signatures related to the mode of action of VPA, such as protein acetylation, developmental changes, and cell migration, emerged from the teratogenic concentrations range. (iii) Cytotoxicity was not accompanied by signatures of newly emerging canonical cell death/stress indicators, but by catabolism and decreased expression of cell cycle associated genes. (iv) Most, but not all of the GO groups and TFBS seen at the highest concentrations were already overrepresented at 350-450 μM. (v) The teratogenicity index reflected this behavior, and thus differed strongly from cytotoxicity. Our findings suggest the use of the highest noncytotoxic drug concentration for gene array toxicogenomics studies, as higher concentrations possibly yield wrong information on the mode of action, and lower drug levels result in decreased gene expression changes and thus a reduced power of the study.
Insights
Valproic acid (VPA) concentration impacts human embryonic stem cell development. Identifying the highest non-cytotoxic VPA dose is crucial for accurate toxicogenomics studies in developmental toxicology.
Area of Science:
- Developmental toxicology
- Systems biology
- Transcriptomics
Background:
- Understanding transcriptome changes at different drug concentrations is vital for developmental toxicology.
- Valproic acid (VPA) is a drug with known developmental effects.
Purpose of the Study:
- To investigate the effects of eight VPA concentrations on human embryonic stem cell differentiation to neuroectoderm.
- To establish design principles for toxicogenomics studies using VPA as a model.
Main Methods:
- Exposure of human embryonic stem cells to VPA (25-1000 μM) during neuroectodermal differentiation.
- Transcriptome analysis to identify differentially regulated genes.
- Biostatistical and systems biology approaches including transcription factor binding site (TFBS) analysis, gene ontology (GO) profiler, and a teratogenicity index.
Main Results:
- A continuous increase in differentially regulated genes with increasing VPA concentration.
- Distinct transcriptome signatures differentiating tolerated, teratogenic, and cytotoxic VPA concentrations.
- Identification of VPA's mode of action signatures (protein acetylation, developmental changes, cell migration) within the teratogenic range.
- Cytotoxicity associated with catabolism and decreased cell cycle gene expression, not canonical stress indicators.
- Teratogenicity index effectively distinguished VPA's developmental toxicity from cytotoxicity.
Conclusions:
- The highest non-cytotoxic drug concentration is recommended for toxicogenomics studies to avoid misleading mode-of-action data.
- Transcriptome profiling combined with systems biology tools can differentiate drug effects and establish concentration-dependent toxicological principles.
More Related Videos
06:40Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
09:34A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
Published on: October 25, 2018
